Ipsen has reported IFRS net income up 28% to €444.5 million for 2025, along with an operating income from activities rising 16.7% to over €1.29 billion, representing a margin of 35.2% of total sales, improved by 2.6 points. The company's sales reached nearly €3.68 billion, an increase of 8.1% on a reported basis and 10.9% at constant exchange rates, driven by all three therapeutic areas (4.1% in oncology, 102.5% in rare diseases, and 9.7% in neurosciences, at constant exchange rates).
Excluding currency effects, the pharmaceutical group claims a 4.3% sales increase for its Somatuline product, while its non-Somatuline drug portfolio posted double-digit growth of 14.2%.
"We have advanced several programs from our R&D product portfolio and strengthened our innovation engine through targeted external innovation operations, including the acquisition of Imcheck Therapeutics," emphasized CEO David Loew.
For 2026, Ipsen is targeting an operating margin from activities above 35% of total sales (including additional R&D spending) and total sales growth of over 13% at constant exchange rates.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (69.2%);
- neuroscience (20.3%);
- rare diseases (10.5%).
At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide.
Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
